MDGL

Analyst Note: MDGL (Madrigal Pharmaceuticals, Inc.)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

Current Price: $505.75 Breakout Level: $615.00 Conservative Entry: None (Breakout not yet fired) Aggressive Entry: $514.57 (Pre-breakout / Forming entry) Extension: —

Structural Classification:

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Secular Exposure: None named at this date.

As of 2026-06-13, there is no named macro or secular thesis attached to this specific setup. The investment case is strictly TACTICAL, driven by the quality of the technical structure (the forming coil) and the immediate business fundamentals disclosed in the most recent reporting period. The conviction must be derived from the setup quality and the strength of the underlying business data, rather than an external thematic narrative.

3. Business Overview

Company: Madrigal Pharmaceuticals, Inc. Industry: Healthcare / Biotechnology Business Model: Commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for metabolic dysfunction-associated steatohepatitis (MASH).

Operational Status & Evidence (as of 2026-06-13): Madrigal has successfully transitioned from a clinical-stage developer to a commercial entity with its lead asset, Rezdiffra (resmetirom).

• Commercial Launch: Rezdiffra received FDA approval in March 2024 and launched commercially in the U.S. in April 2024. It also received conditional marketing authorization from the European Commission and launched in Germany in September 2025.
• Revenue Performance: The company has demonstrated rapid commercial traction. For the year ended December 31, 2025, the company generated $958.4 million in product revenue. In the first quarter of 2026, net sales reached $311.3 million, representing a year-over-year growth of 127% compared to the prior year period.
• Patient Base: As of the end of Q1 2026, there were more than 42,250 active patients on Rezdiffra. Management states that Rezdiffra has achieved "blockbuster status," generating more than $1.1 billion in net sales over the last 12 months.
• Market Opportunity: Management estimates the U.S. addressable market for patients under specialist care has grown nearly 50% from 315,000 patients (end of 2023) to 460,000 patients (end of 2025). Management believes the "F4C" (Fibrosis to Cirrhosis) opportunity could double the current addressable market, with approximately 245,000 patients currently under specialist care in the U.S.
• Pricing & Margins: Management expects the gross-to-net discount to remain in the mid- to high 30s for the remainder of 2026.

4. Archetype and Conviction Analysis

Archetype: Margin Inflector Rationale: The company fits the Margin Inflector archetype. The business model has shifted from high R&D burn to high-margin commercial revenue generation. The evidence shows a rapid scaling of revenue ($958.4M in 2025 to $311.3M in Q1 2026 alone) with a clear path to profitability as fixed costs are amortized over a growing patient base. The "blockbuster" designation and the 127% YoY growth indicate that the commercial engine is inflecting margins positively.

Conviction Stack:

• Thesis Strength: Moderate. The thesis is tactical and setup-led, lacking a broad secular macro overlay, but the business fundamentals are robust.
• Evidence Quality: High. The evidence base is dense with primary source data (earnings transcripts and SEC filings) from May 2026 and February 2026, providing concrete figures on sales, patient counts, and market size.
• Rerating Potential: High. The combination of blockbuster sales status, a growing addressable market (460k patients), and a low market penetration rate suggests significant room for multiple expansion if the breakout confirms.

5. Invalidation, Strengthening, and Gaps

Invalidation:

Strengthening:

• Technical: A daily close above $615.00 would confirm the breakout, transitioning the coil to a "Confirmed-Active" state.
• Fundamental: Continued acceleration in quarterly sales growth or an update on the F4C study showing accelerated patient identification would strengthen the commercial thesis.

Gaps in Evidence:

• Long-term Profitability: While revenue is strong, specific details on the path to GAAP net income or cash flow breakeven for the full year 2026 are not explicitly detailed in the provided evidence snippets, though the "blockbuster" status implies strong cash generation.
• Competitive Landscape: The evidence focuses heavily on Madrigal's internal metrics and market size but does not explicitly detail competitive dynamics or pipeline threats from other MASH therapies in the 2026 landscape.
• European Sales Data: While the German launch is noted, specific revenue contribution from the European market is not quantified in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Rezdiffra generated $1.1B in net sales over the last 12 months; Q1 2026 sales grew 127% YoY to $311.3M; 42,250 active patients recorded; addressable market grew 50% to 460,000 patients. Key risks: Technical setup remains in "forming" state awaiting $615 breakout; F4C and MAESTRO-NASH trial readouts delayed or negative; gross-to-net discount pressure remains in mid-to-high 30s. Expected path: Management expects continued patient growth and market expansion; structural implication is a potential breakout above $615 if commercial momentum holds. Expected horizon: 3 to 6 months for the technical setup to resolve (breakout or invalidation). Failure mode to watch: A daily close below $499.34, which would invalidate the forming coil structure.